Details of the Drug Combination

General Information of Drug Combination (ID: DCW5NJK)

Drug Combination Name
Pretomanid Moxifloxacin
Indication
Disease Entry Status REF
Pulmonary Tuberculosis Phase 1 [1]
Component Drugs Pretomanid   DMDYA31 Moxifloxacin   DMU8V4S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Pretomanid
Disease Entry ICD 11 Status REF
Tuberculosis 1B10-1B14 Approved [2]
Mycobacterium infection 1B10-1B21 Phase 3 [3]
Pretomanid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium Mycolic acid synthase (MycB cma) TT08ESN CMAS1_MYCTU; CMAS2_MYCTU; CMAS3_MYCTU Inhibitor [2]
------------------------------------------------------------------------------------
Pretomanid Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Moxifloxacin
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [4]
Mycoplasma pneumoniae pneumonia N.A. Approved [5]
Peritonitis N.A. Approved [5]
Pneumonic plague N.A. Approved [5]
Septicemic plague N.A. Approved [5]
Staphylococcal pneumonia N.A. Approved [5]
Staphylococcus aureus infection N.A. Approved [5]
Streptococcal pneumonia N.A. Approved [5]
Tuberculosis 1B10-1B14 Approved [5]
Pneumonia caused by chlamydia N.A. Investigative [5]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [5]
Moxifloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [7]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01215851) Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 ClinicalTrials.gov (NCT02342886) Shortening Treatment by Advancing Novel Drugs. U.S. National Institutes of Health.
4 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
5 Moxifloxacin FDA Label
6 FDA briefing document - pretomanid tablet, 200 mg meeting of the antimicrobial drugs advisory committee (AMDAC).
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.